Agenus (AGEN) News Today $1.58 -0.06 (-3.37%) As of 01:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Brokerages Set Agenus Inc. (NASDAQ:AGEN) Target Price at $8.75March 29, 2025 | americanbankingnews.comAgenus to Present New BOT/BAL Data in Two Presentations at AACR 2025March 25, 2025 | businesswire.comAgenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment ...March 19, 2025 | gurufocus.comAgenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment InnovationMarch 19, 2025 | businesswire.comRobert W. Baird Cuts Agenus (NASDAQ:AGEN) Price Target to $3.00Robert W. Baird decreased their price target on shares of Agenus from $6.00 to $3.00 and set a "neutral" rating for the company in a report on Wednesday.March 13, 2025 | marketbeat.comAgenus (NASDAQ:AGEN) Given "Neutral" Rating at HC WainwrightHC Wainwright reissued a "neutral" rating on shares of Agenus in a research note on Wednesday.March 13, 2025 | marketbeat.comQ4 2024 Agenus Inc Earnings CallMarch 13, 2025 | uk.finance.yahoo.comAgenus price target lowered to $3 from $6 at BairdMarch 12, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comAgenus (NASDAQ:AGEN) Releases Earnings Results, Beats Estimates By $0.32 EPSAgenus (NASDAQ:AGEN - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.36) by $0.32.March 12, 2025 | marketbeat.comWilliam Blair Sticks to Its Hold Rating for Agenus (AGEN)March 11, 2025 | markets.businessinsider.comAgenus reports Q4 EPS ($2.04), consensus ($2.54)March 11, 2025 | markets.businessinsider.comAgenus (AGEN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | msn.comAgenus stock falls after revenue missMarch 11, 2025 | msn.comAgenus Inc. (AGEN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comAgenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL ProgramMarch 11, 2025 | financialpost.comAgenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL ProgramMarch 11, 2025 | businesswire.comAgenus Q4 2024 Earnings PreviewMarch 10, 2025 | seekingalpha.comAgenus (AGEN) to Release Earnings on TuesdayAgenus (NASDAQ:AGEN) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669789)March 4, 2025 | marketbeat.comAgenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by BrokeragesAgenus Inc. (NASDAQ:AGEN - Get Free Report) has been given an average rating of "Hold" by the six analysts that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company.March 1, 2025 | marketbeat.comAgenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed PublicationsFebruary 26, 2025 | finance.yahoo.comAgenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed PublicationsFebruary 26, 2025 | businesswire.comAgenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFebruary 25, 2025 | businesswire.comAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportFebruary 25, 2025 | finance.yahoo.comAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial ReportFebruary 25, 2025 | businesswire.comCORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO ...February 24, 2025 | gurufocus.comCORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingFebruary 23, 2025 | businesswire.comAgenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingFebruary 12, 2025 | finance.yahoo.comAgenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual MeetingFebruary 12, 2025 | businesswire.comIncyte terminates license agreement with AgenusFebruary 11, 2025 | markets.businessinsider.comKuehn Law Encourages Investors of Agenus Inc. to Contact Law FirmFebruary 4, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by AnalystsAgenus Inc. (NASDAQ:AGEN - Get Free Report) has received a consensus rating of "Hold" from the six research firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-mFebruary 4, 2025 | marketbeat.comSaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine DevelopmentJanuary 30, 2025 | uk.finance.yahoo.comFY2024 Earnings Forecast for Agenus Issued By William BlairAgenus Inc. (NASDAQ:AGEN - Free Report) - Investment analysts at William Blair upped their FY2024 EPS estimates for shares of Agenus in a note issued to investors on Monday, January 27th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($14.59) perJanuary 30, 2025 | marketbeat.comAgenus reports publication of data from bot/bal combination in JOCOJanuary 30, 2025 | markets.businessinsider.comAgenus reports promising sarcoma study resultsJanuary 30, 2025 | msn.comAgenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic SarcomasJanuary 29, 2025 | businesswire.comH.C. Wainwright Sticks to Their Hold Rating for Agenus (AGEN)January 27, 2025 | markets.businessinsider.comAgenus presents updated bot/bal data at ASCO-GI, says H.C. WainwrightJanuary 27, 2025 | markets.businessinsider.comAgenus (AGEN) Receives a Hold from H.C. WainwrightJanuary 23, 2025 | markets.businessinsider.comAgenus reports promising colorectal cancer treatment dataJanuary 22, 2025 | msn.comAgenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced DiseaseJanuary 22, 2025 | businesswire.comHC Wainwright Reiterates Neutral Rating for Agenus (NASDAQ:AGEN)HC Wainwright restated a "neutral" rating on shares of Agenus in a report on Wednesday.January 22, 2025 | marketbeat.comSaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant DevelopmentJanuary 21, 2025 | businesswire.comAgenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by AnalystsShares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation tJanuary 10, 2025 | marketbeat.comPromising Potential for Agenus in Oncology: Buy Rating Reinforced by Strong CRC and Gastric Cancer Therapy ProspectsJanuary 8, 2025 | markets.businessinsider.comAgenus Inc. (NASDAQ:AGEN) Short Interest Up 6.5% in DecemberAgenus Inc. (NASDAQ:AGEN - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 2,930,000 shares, a growth of 6.5% from the November 30th total of 2,750,000 shares. Approximately 13.1% of the shares of the company are short sold. Based on an average daily trading volume, of 494,100 shares, the short-interest ratio is presently 5.9 days.December 31, 2024 | marketbeat.comAgenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersDecember 18, 2024 | businesswire.comVaccine Adjuvants Market with Business Strategy, Key Drivers, Opportunities, Top Key Companies Analysis and ForecastDecember 13, 2024 | theglobeandmail.comTanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With AgenusDecember 12, 2024 | finance.yahoo.com Remove Ads Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address AGEN Media Mentions By Week AGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGEN News Sentiment▼0.000.57▲Average Medical News Sentiment AGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGEN Articles This Week▼16▲AGEN Articles Average Week Remove Ads Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sangamo Therapeutics News Regulus Therapeutics News Lexicon Pharmaceuticals News Achieve Life Sciences News Fortress Biotech News Dominari News Curis News Bolt Biotherapeutics News SAB Biotherapeutics News Molecular Templates News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGEN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AGEN Stock Free AGEN Stock Alerts